Evaluation of a DNA Demethylating Agent in Combination with All-trans Retinoic Acid for IDH1-mutant Gliomas

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2021 Dec 1

PMID 34850159

Citations 5

Authors

Marina da Costa Rosa

Alex Shimura Yamashita

Gregory J Riggins

Affiliations

Soon will be listed here.

Abstract

Background: Isocitrate Dehydrogenase 1/2 (IDH1/2) mutations are diagnostic for Astrocytoma or Oligodendroglioma, IDH-mutant. In these IDH-mutant gliomas, retinoic acid-related gene expression is commonly silenced by DNA hypermethylation. DNA demethylating agents can epigenetically reprogram IDH-mutant cells and reduce proliferation, likely by re-expression of silenced tumor suppressor pathways. We hypothesized that DNA demethylation might restore the retinoic acid pathway and slow tumor growth. This was the rationale for a preclinical evaluation combining the DNA demethylating agent, 5-Azacytidine (5-Aza), and retinoic acid pathway activation with all-trans retinoic acid (atRA) in IDH-mutant glioma.

Methods: In this study, we evaluated the effect of 5-Aza and atRA combination on cell proliferation, apoptosis, and gene expression in human glioma cells. In addition, the efficacy of this combination was tested in patient-derived xenograft (PDX) bearing the IDH1R132H mutation, utilizing subcutaneous and orthotopic models.

Results: 5-Aza reduced the DNA methylation profile and increased the gene expression of retinoic acid-related genes. Combination of 5-Aza and atRA reduced cell growth, increased differentiation marker expression, and apoptosis in IDH1R132H glioma cells. Mechanistically, 5-Aza sensitized IDHIR132H glioma cells to atRA via upregulation of the retinoic acid pathway. Importantly, the drug combination reduced significantly the growth rate of subcutaneous tumors, but in an orthotopic mouse model, the combination did not improve survival and 5-Aza alone provided the best survival benefit.

Conclusion: Use of DNA demethylating agent in combination with retinoids shows promise, but further optimization and preclinical studies are required for treatment of intracranial IDH-mutant gliomas.

Citing Articles

Cell-Based Glioma Models for Anticancer Drug Screening: From Conventional Adherent Cell Cultures to Tumor-Specific Three-Dimensional Constructs.

Lanskikh D, Kuziakova O, Baklanov I, Penkova A, Doroshenko V, Buriak I Cells. 2025; 13(24.

PMID: 39768176 PMC: 11674823. DOI: 10.3390/cells13242085.

Exosomes as drug delivery systems in glioma immunotherapy.

Hao X, Wang S, Wang L, Li J, Li Y, Liu J J Nanobiotechnology. 2024; 22(1):340.

PMID: 38890722 PMC: 11184820. DOI: 10.1186/s12951-024-02611-4.

RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.

Zhu S, Luo Y, Li K, Mei C, Wang Y, Jiang L Sci Adv. 2024; 10(16):eadi1782.

PMID: 38630819 PMC: 11023509. DOI: 10.1126/sciadv.adi1782.

Qiao Q, Wang Y, Zhang R, Pang Q Transl Cancer Res. 2022; 11(7):2157-2174.

PMID: 35966301 PMC: 9372237. DOI: 10.21037/tcr-22-310.

Targeting IDH-Mutant Glioma.

Miller J Neurotherapeutics. 2022; 19(6):1724-1732.

PMID: 35476295 PMC: 9723039. DOI: 10.1007/s13311-022-01238-3.

References

Boutzen H, Saland E, Larrue C, De Toni F, Gales L, Castelli F . Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016; 213(4):483-97. PMC: 4821643. DOI: 10.1084/jem.20150736. View

Tsai H, Li H, Van Neste L, Cai Y, Robert C, Rassool F . Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012; 21(3):430-46. PMC: 3312044. DOI: 10.1016/j.ccr.2011.12.029. View

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

Linnekamp J, Butter R, Spijker R, Medema J, van Laarhoven H . Clinical and biological effects of demethylating agents on solid tumours - A systematic review. Cancer Treat Rev. 2017; 54:10-23. DOI: 10.1016/j.ctrv.2017.01.004. View

Guilhamon P, Eskandarpour M, Halai D, Wilson G, Feber A, Teschendorff A . Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun. 2013; 4:2166. PMC: 3759038. DOI: 10.1038/ncomms3166. View

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View

Borodovsky A, Meeker A, Kirkness E, Zhao Q, Eberhart C, Gallia G . A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. J Neurooncol. 2014; 121(3):479-87. PMC: 4648276. DOI: 10.1007/s11060-014-1672-2. View

Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin C . Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene. 2011; 30(31):3454-67. PMC: 3955956. DOI: 10.1038/onc.2011.58. View

10.

Di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C . Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med. 2014; 41:1-115. DOI: 10.1016/j.mam.2014.12.003. View

11.

Duncan C, Barwick B, Jin G, Rago C, Kapoor-Vazirani P, Powell D . A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012; 22(12):2339-55. PMC: 3514664. DOI: 10.1101/gr.132738.111. View

12.

Saha S, Parachoniak C, Ghanta K, Fitamant J, Ross K, Najem M . Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014; 513(7516):110-4. PMC: 4499230. DOI: 10.1038/nature13441. View

13.

Milanovic D, Sticht C, Rohrich M, Maier P, Grosu A, Herskind C . Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo. Oncotarget. 2015; 6(30):28938-48. PMC: 4745702. DOI: 10.18632/oncotarget.4727. View

14.

Esteller M, Guo M, Moreno V, Peinado M, Capella G, Galm O . Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res. 2002; 62(20):5902-5. View

15.

Lu C, Ward P, Kapoor G, Rohle D, Turcan S, Abdel-Wahab O . IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483(7390):474-8. PMC: 3478770. DOI: 10.1038/nature10860. View

16.

Borodovsky A, Salmasi V, Turcan S, Fabius A, Baia G, Eberhart C . 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013; 4(10):1737-47. PMC: 3858560. DOI: 10.18632/oncotarget.1408. View

17.

Penas-Prado M, Hess K, Fisch M, Lagrone L, Groves M, Levin V . Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2014; 17(2):266-73. PMC: 4288521. DOI: 10.1093/neuonc/nou155. View

18.

Yamashita A, da Costa Rosa M, Borodovsky A, Festuccia W, Chan T, Riggins G . Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol. 2018; 21(2):189-200. PMC: 6374765. DOI: 10.1093/neuonc/noy146. View

19.

Ionta M, Rosa M, Almeida R, Freitas V, Rezende-Teixeira P, Machado-Santelli G . Retinoic acid and cAMP inhibit rat hepatocellular carcinoma cell proliferation and enhance cell differentiation. Braz J Med Biol Res. 2012; 45(8):721-9. PMC: 3854244. DOI: 10.1590/s0100-879x2012007500087. View

20.

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View